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Uterine leiomyosarcoma (ULMS) is an uncommon mesenchy-
mal neoplasm accounting for 1.3% of all uterine malignancies 
and 30% to 40% of all uterine sarcomas [1]. In contrast to 
endometrial carcinomas which most commonly metastasize 
to the lymph nodes, ULMS have a high propensity for hema-
togeneous spread most commonly to the lungs. The standard 
management of localized ULMS is surgical and includes total 
abdominal hysterectomy with or without salpingo-oopho-
rotectomy. To date there are no data which demonstrate an 
overall survival benefit from either adjuvant radiotherapy or 
adjuvant chemotherapy. ULMS are aggressive tumors with 
poor 5-year survival rates which vary between 15% and 25% 
for all stages of disease [2]. The major factors determining the 
5-year disease-specific survival (DSS) include demographic 
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Objective: To describe metastatic pattern of uterine leiomyosarcomas (ULMS) and correlate it with clinical and histopathologic 
parameters.
Methods: we included 113 women (mean age, 53 years; range, 29 to 72 years) with histopathology-confirmed ULMS from 2000 
to 2012. Distribution of metastases was noted from imaging by two radiologists in consensus. Predictors of development of 
metastases were analyzed with univariate and multivariate analysis. Impact of various clinical and histopathologic parameters 
on survival was compared using Log-rank test and Cox proportional hazard regression model.
Results: Distant metastases were seen in 81.4% (92/113) of the patients after median interval of 7 months (interquartile 
range, 1 to 21). Lung was most common site of metastases (74%) followed by peritoneum (41%), bones (33%), and liver 
(27%). Local tumor recurrence was noted in 57 patients (50%), 51 of whom had distant metastases. Statistically significant 
correlation was noted between local recurrence and peritoneal metastases (p<0.001) and between lung and other common 
sites of hematogeneous metastases (p<0.05). Age, serosal involvement, local recurrence, and the International Federation of 
Gynecology and Obstetrics (FIGO) stage were predictive factors for metastases. At the time of reporting, 65% (74/113) of the 
patients have died; median survival was 45 months. Stage, local recurrence, and age were poor prognostic factors.
Conclusion: ULMS metastasizes most frequently to lung, peritoneum, bone, and liver. Local recurrence was associated with 
peritoneal spread and lung metastases with other sites of hematogeneous metastases. Age, FIGO stage and local recurrence 
predicted metastatic disease and advanced stage, older age and local recurrence predicted poor outcome.
Keywords: Leiomyosarcoma, Neoplasm recurrence, Prognosis, Proportional Hazards Models
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factors such as age and race, histopathological factors such as 
stage, mitotic index, and lymphovascular invasion [3,4].
Advances in imaging techniques in the last few decades have 
enabled timely detection of recurrent and metastatic disease 
in oncology practice. Data pertaining to the metastatic pat-
tern of ULMS has not been adequately captured in any of the 
prior studies including the largest study of 1,396 patients with 
ULMS obtained from the Surveillance, Epidemiology, and End 
Results (SEER) data base [4]. Most of the existing studies have 
focused mainly on the management and prognostic factors 
of ULMS [3,5-7]. The predictors of metastases, however have 
not been analyzed in any of these studies. With respect to 
the metastatic pattern, the literature is replete with several 
individual case reports of atypical metastatic sites [8-17]. In the 
large series, the emphasis has always been on lymph nodal 
involvement and the need for lymphadenectomy [6]. The pur-
pose of our study was therefore to review a large database of 
patients with ULMS at our tertiary cancer institute to describe 
the pattern of metastasis in ULMS and provide a correlation 
with various clinical and histopathologic parameters.
MATERIAL AND METHODS
In this Health Insurance Portability and Accountability Act-
compliant institutional review board-approved retrospective 
study, the electronic medical records and imaging studies 
of 113 women (mean age, 53 years; range, 29 to 72 years) 
with histopathology-confirmed ULMS seen at our institution 
between January, 2000 and December, 2012 were reviewed. 
Patients with leiomyosarcoma who were treated with morcel-
lation were excluded from the study. The demographic data, 
the date of diagnosis of ULMS and the International Federa-
tion of Gynecology and Obstetrics (FIGO) stage 2009 either 
surgical in patients undergoing surgery or clinical in patients 
without surgery was recorded in all the patients. The presence 
of metastases at presentation, the time from diagnosis to 
metastases and local recurrence, the date of last follow-up 
and the outcome were also extracted from the electronic 
medical records. The histopathological features of the primary 
tumor including the size of the tumor, serosal and cervical 
involvement, mitotic count, nuclear atypia, lymphovascular 
invasion, and necrosis were recorded.
All the available computed tomography (CT) scans in the 
113 patients were systematically reviewed in consensus by 
two cancer imaging fellowship-trained radiologists with 8 
and 15 years of experience. The restaging CT scans were per-
formed at 6 to 8 weeks interval according to the institutional 
protocol. In total 892 restaging CT scans were reviewed. The 
presence or absence of local recurrence, site, number, and 
size of the distant metastasis and the date of detection of the 
recurrent/ metastatic disease were recorded for each patient. 
The recurrent or metastatic disease was confirmed either by 
biopsy or by the presence of unequivocal progression on 
follow-up imaging. Nodal metastases was confirmed either 
at histopathology or was presumed based on the typical 
anatomic location on imaging.
The predictors of development of metastases and impact 
of various clinical and histopathologic parameters on survival 
were statistically analyzed. The predictive value of age, tumor 
size, FIGO stage, presence or absence of necrosis, mitotic 
count, serosal involvement, cervical involvement, and local 
recurrence for development of metastatic disease was as-
sessed using univariate and multivariate analysis; multivariate 
analysis was performed using logistic regression. For the 
purpose of this analysis, we divided the tumor stage into three 
groups, stage 1, stage 2 or 3, and stage 4. This was done partly 
because there were fewer patients in stages 2 and 3, but also 
because there is significant prognostic overlap between stage 
2 and 3 by both FIGO and American Joint Committee on 
Cancer (AJCC) classifications [18,19]. 
Survival between the three FIGO stage-groups was com-
pared using Log-rank test. The three FIGO stage-groups were 
also individually compared with each other for differences 
in survival. The effect of age, tumor size, stage, and presence 
of local recurrence on survival was assessed in a multivariate 
analysis using the Cox proportional hazard regression model. 
Time to local recurrence was correlated with size of the 
primary tumor using Spearman correlation. 
RESULTS 
1. Patient and tumor characteristics 
Of the 113 patients, 76 patients (67%) were ≥50 years of age 
at the time of first diagnosis of ULMS. The mean tumor size 
was 10.9 cm (range, 0.5 to 25 cm) with 49 tumors >10 cm in 
size. Of the 113 patients, 54 (48%) had FIGO stage I tumors, 17 
(15%) had stage II tumors, six (5%) had stage III, and 32 (28%) 
had stage IV tumors (Table 1). The FIGO stage was unknown 
in four patients. Surgery for primary disease was performed in 
111 patients while two patients received only chemotherapy. 
Of the 111 patients who underwent surgery, 99 patients under-
went total abdominal hysterectomy with or without salpingo-
oopphrectomy, 10 patients had supracervial/ subtotal hyster-
ectomy and two patients underwent radical hysterectomy. In 
12 patients, a myomectomy was performed initially which was 
followed by total hysterectomy due to detection of ULMS at Sree Harsha Tirumani, et al.
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histopathology (one patient diagnosed intraoperatively on fro-
zen section specimen). Pelvic node assessment was performed 
in 33 patients with positive nodes seen at histopathology in 
one patient. Neoadjuvant chemotherapy was administered in 
three patients. Postoperative chemotherapy was administered 
in 92 patients 23 after development of recurrent/metastatic 
disease. Postoperative radiotherapy was administered in 
56 patients, 33 after development of recurrent/metastatic 
disease. At histopathology, serosal involvement was present 
in 22, absent in 37 and not available in 54 patients. Cervical 
involvement was present in 13, absent in 76 and not available 
in 24 patients. The mean mitotic count was 24 per 10 high 
power fields (range, 0 to 97). Necrosis was present in 76 cases, 
absent in 13 cases and was not commented in 24 cases. 
2. Distribution of metastases
Of the 113 patients, 92 (81%) had radiographic metastasis at 
any point in the follow-up period of 45 months (range, 4 to 
271 months), 12 (10.6%) of whom presented with metastatic 
disease. The time from diagnosis to metastases was 7 months 
(interquartile range [IQR], 1 to 21). Lung was the most com-
mon site of metastases (84 patients, 74%) followed by the 
peritoneum (46 patients, 41%), bones (37patients, 33%), and 
liver (30 patients, 27%). Table 2 shows the distribution and 
frequency of metastases in ULMS. At least one of the three 
most common sites of metastases, i.e., lung, peritoneum, and 
Table 1. Demographic, tumor, and treatment characteristics of 
patients with uterine leiomyosarcoma (n=113)
Variable No. (%)
Age (yr) 　
    <50 37 (33)
    ≥50 76 (67)
Tumor size (cm) 　
    <5 8 (7)
    5–10 38 (34)
    >10 49 (43)
    Unknown 18 (16)
FIGO stage 　
    I 54 (48)
    II 17 (15)
    III 6 (5)
    IV 32 (28)
    Unknown 4 (4)
Neoadjuvant chemotherapy 3
Primary treatment 　
    Surgery 111 (98)
    Chemotherapy 2 (2)
Adjuvant treatment
    Chemotherapy 92 (23 after metastases)
    Radiotherapy 56 (33 after metastases)
Histopathology     　
    Serosal involvement 　
        Present  22 (19)
        Absent  37 (33)
        Unknown 54 (48)
    Cervical involvement 　
        Present  13 (12)
        Absent  76 (67)
        Unknown 24 (21)
    Mean mitotic count 24/10 high power fields
Necrosis 　
    Present  76 (67)
    Absent  13 (12)
    Unknown 24 (21)
Local recurrence 　
    Yes 57 (50)
    No 56 (50)
Distant metastases 　
    Yes 92 (81)
    No 21 (19)
Death 　
    Yes 74 (65)
    No 39 (35)
FIGO, the International Federation of Gynecology and Obstetrics.
Table 2. Sties of metastasis of uterine leiomyosarcoma
Location No. (%)
Lung 84 (74)
Peritoneum 46 (41)
Bones 37 (33)
Liver 30 (27)
Muscles 29 (26)
Lymph nodes 25 (22)
Subcutaneous 17 (15)
Kidney 6 (5)
Pancreas 6 (5)
Brain 5 (4)
Cardiac 5 (4)
Adrenal 2 (2)
Spleen 1 (1)
Thyroid 1 (1)
Breast 1 (1)
Vagina 1 (1)
Orbit 1 (1)
Total 297Metastatic pattern of uterine leiomyosarcoma 
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bone were involved in all the 92 patients with metastases. 
Thirty eight of the 92 patients had metastases in all the three 
common sites while 47/92 patients had metastases in the 
lung and peritoneum. In 64/92 patients with metastases, lung 
was the first site of metastases, nine of whom had concurrent 
metastases at other sites.
Lung metastases were seen as pulmonary nodules and masses 
varying in size between 5 mm to 14 cm with cavitation noted in 
larger nodules. Pleural metastases were noted in 27/84 patients 
with lung metastases. Peritoneal involvement in all 46 patients 
was in the form of peritoneal nodules and masses varying in size 
from 1 to 18 cm, located in the peritoneal cavity including the 
mesentery, omentum, paracolic gutters, bowel serosa, lesser 
sac, and pelvis. Two patients developed tumor-bowel fistula. 
Bone metastases, the third most common site of metastases 
seen in 37 patients, were lytic with soft tissue component in 30 
patients and sclerotic in seven patients. There was associated 
epidural soft tissue in four cases. All 30 patients with hepatic 
metastases had multiple lesions which were low in attenua-
tion.
The other sites of metastases were skeletal muscles (29 patients, 
26%), lymph nodes (25 patients, 22%), and subcutaneous soft 
tissues (17 patients, 15%). Of the 25 patients with lymph nodal 
metastases, 12 had involvement of the supradiaphragmatic 
nodes mainly the mediastinal and hilar nodes; retroperitoneal 
node involvement was seen in five cases and pelvic nodal 
metastases in six cases. Renal and pancreatic metastases were 
seen in six cases each. Brain and cardiac metastases were 
found in five patients each. Adrenal glands, spleen, thyroid, 
breast, orbit, and vagina were uncommon metastatic sites.
3. Predictors of metastases 
Analysis of the various predictors of metastases showed 
that age, serosal involvement, local recurrence, and FIGO 
stage had statistically significant predictive value (Table 3). Ad 
hoc analysis of age as predictor for metastases, showed that 
67/76 patients with ≥50 years of age developed metastases 
while 25/37 patients <50 years of age developed metastases. 
The difference between these two groups was statistically 
significant (multivariate analysis: p=0.03). Distant metastases 
Table 3. Univariate and multivariate associations between metastases and clinicopathologic factors
Parameter No.
Univariate Multivariate
Metastasis (–) Metastasis (+) p-value OR (95% CI) p-value
Age (yr) 0.01 0.03
    <50 37 12 25 Reference
    ≥50 76   9 67 1.56 (1.04-4.06)
Serosal involvement*  0.02 0.006
    Absent 37   2 35 Reference
    Present 22  6 16 45.78 (2.24-93.71)
Local recurrence  0.03 0.01
    Absent 56 15 41 Reference
    Present 57   6 51 1.10 (1.02-1.19)
FIGO stage* 0.20 0.03
    I 54 14 40 Reference
    II–III 23   3 20 2.27 (1.27-7.06)
    IV 32   4 28 4.20 (1.36-9.77)
Tumor size (cm), mean (range) 9.8 (0.5-19) 11.1 (3-25) 0.54 1.54 (0.79-4.99) 0.81
Cervical involvement* 0.28 0.09
    Absent 76 18 58 Reference
    Present 13   1 12 1.04 (0.93-1.16)
Mitotic count/HPF, mean (range) 19 (0-42) 24 (0-97) 0.08 0.87 (0.63-1.23) 0.09
Necrosis* 0.12 0.05
    Absent 13   5   8 Reference
    Present 76 13 63 1.38 (0.18-10.41)
HPF, High power fields. 
*Cases with unknown parameters were excluded from analysis. Sree Harsha Tirumani, et al.
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developed in 16/22 patients with serosal involvement 
(p=0.006) and 51/57 patients with local recurrence (p=0.01). 
With respect to FIGO stage, 40/54 patient with stage I, 20/23 
patients with stage II/III and 28/32 patients with stage IV 
disease developed metastatic disease (p=0.03). The size of 
the tumor (p=0.81), cervical involvement (p=0.09), mitotic 
count (p=0.09), and necrosis (p=0.05) were not predictive of 
metastases.
4. Correlation of local recurrence with metastatic pattern
During the median follow-up of 45 months (range, 4 to 271 
months), local tumor recurrence developed in 57 patients 
(50%). Distant metastases developed in 51 of these 57 patients 
with local recurrence. Distant metastases developed before 
local recurrence in 21/51 patients, after the local recurrence 
in 14/51 patients and at the same time as local recurrence in 
16/51 patients. Analyses of the pattern of distant metastases in 
the 21 patients who developed distant metastases developed 
before local recurrence showed that lung was the first site 
of metastases in 19 patients, one of them having concurrent 
peritoneal metastases; bone and subcutaneous metastases 
were the first site in the one each remaining patient. In the 
14 patients who developed local recurrence before distant 
metastases, lung was the first site of metastases in six patients, 
peritoneal cavity was the first site in four patients, liver in 
two patients, bone in one patient, and multiple sites (lung, 
peritoneum, bone) in one another patient. These differences 
were; however, not statistically significant (p>0.05). Over all, 
of the 57 patients with local recurrence, 42 developed lung 
metastases, and 34 developed peritoneal metastases. We 
correlated local recurrence with the five most common sites 
of metastases- lung, peritoneum, bones, liver, and muscles 
which showed statistically significant correlation between 
local recurrence and peritoneal metastases (Fisher exact test, 
p<0.001) and no significant correlation with the other sites 
of metastases. There was statistically significant correlation 
between lung metastases and other common sites of 
hematogeneous metastases including bone (Fisher exact test, 
p=0.0026), liver (Fisher exact test, p<0.001), and muscle (Fisher 
exact test, p=0.0065).
5. Predictors of survival
The median metastases-free survival in this cohort was 7 
months (IQR, 1 to 21 months). At the time of last follow-up, 
74/113 patients (65%) have died. Stage-wise analysis showed 
that 25/54 patients with stage I disease at presentation, 16/23 
patients with stage II/III, and 29/32 patients with stage IV 
disease have died. The median overall survival for all patients 
was 45 months (IQR, 25 to 74 months). The median survival 
of patients with FIGO stage I, II/III, and IV tumors was 63.5 
months (IQR, 35 to 121 months), 45 months (IQR, 31 to 61 
months), and 23 months (IQR, 11 to 38 months), respectively 
(p<0.001). There was statistically significant survival difference 
between stage I and stage II/III (p=0.004), stage II/III and stage 
IV disease (p=0.02), and stage I and IV (p<0.001). Analysis of 
predictors of survival using the Cox proportional regression 
model showed that stage, local recurrence, and age adversely 
affected survival (Table 4). Patients with higher FIGO stage 
and patients with local recurrence had higher risk of death 
with hazard ratios of 2.19 (range, 1.56 to 3.08) and 2.03 (range, 
0.26 to 3.27) respectively. Elderly patients also had statistically 
significant minimal increase in risk of death with hazard ratio 
of 1.03 (range, 1.001 to 1.06), although the clinical relevance of 
this minimal increase in risk is uncertain. The size of the primary 
tumor did not significantly affect the survival. There was no 
significant correlation between the size of primary tumor and 
local recurrence-free interval (Spearman rank correlation, 0.008). 
DISCUSSION
The diagnosis of ULMS often occurs in retrospect after 
surgical resection of a presumed benign uterine neoplasm and 
therefore, patients often do not undergo preoperative staging 
work up. Bernstein-Molho et al. [5] found in their study of 33 
patients that this lack of preoperative staging as one of the 
causes for the short disease-free interval in their study. The Na-
tional Comprehensive Cancer Network (NCCN) clinical practice 
guidelines for uterine sarcomas recommend hysterectomy as 
the initial treatment of choice for all medically operable patients 
Table 4. Multivariate survival analysis of clinicopathologic factors in 
terms of metastasis-free survival
Parameter No. Hazard ratio 95% CI p-value
FIGO stage <0.001
    I 54 Reference
    II–III 23 2.19 1.09–4.34
    IV 32 15.23 6.83–34.76
Local recurrence 0.004
    Absent 56 Reference
    Present 57 2.03 0.26–3.27
Age (yr) 0.045
    <50 37 Reference
    ≥50 76 1.03 1.001–1.06
Tumor size (cm) 1.05 0.99–1.11 0.07
CI, confidence interval; FIGO, International Federation of Gynecology 
and Obstetrics. Metastatic pattern of uterine leiomyosarcoma 
J Gynecol Oncol Vol. 25, No. 4:306-312 www.ejgo.org 311
with disease limited to the uterus [20]. However, in patients 
with suspected extrauterine disease spread, additional surgical 
resection of metastatic disease, or systemic chemotherapy is 
recommended after radiological staging. This underscores the 
significance of the knowledge of the metastatic pattern which 
helps in planning treatment strategies.
In the autopsy series of 73 patients with uterine sarcomas 
by Rose et al. [21] which included 19 patients with ULMS, 
the most common site of metastases was peritoneal cavity 
followed by lung, lymph nodes, and liver. The most common 
sites of metastases in our study in descending order of involve-
ment were lung, peritoneal cavity, bone, and liver. Though this 
pattern is slightly different from the autopsy series of Rose et 
al. [21] which can be due to inclusion of all types of sarcomas 
in their study and different management strategies, it is in 
agreement with other studies. In the study of 126 patients with 
ULMS by Gadducci et al. [6], of the 30 patients with distant 
metastases, lung, peritoneal cavity, liver, and bone were the 
most common sites of metastases. Similarly, in a study of 71 
patients with ULMS, Mayerhofer et al. [7] found lung to be the 
most common site of metastases. The high incidence of lung 
metastases (64/92 patients in our study) justifies the inclusion 
of thoracic imaging in the follow-up of patients with ULMS. 
The management of pelvic and para-aortic lymph nodes in 
ULMS has been controversial with no clear recommendations 
by the NCCN guidelines [20]. Though the overall incidence 
of nodal metastases in our study was 22%, the incidence of 
pelvic and para-aortic nodal metastases was 8.8% which is in 
agreement with earlier literature. In the largest study of 1396 
ULMS patients till date by Kapp et al. [4], the incidence of 
nodal metastasis was 6.6% in the 348 patients who underwent 
lymphadenectomy. The presence of nodal metastases de-
creased the 5-year survival from 64% in node negative cases 
to 26% in node positive cases in their study. The incidence of 
intrathoracic nodal metastases (10.6%) reported in our study 
is lower than that reported by Rose et al. (23.6%) [21].
The metastasis-free interval was 7 months in our study. This 
was shorter than that observed by Gadducci et al. [6] (12 to 
16 months) but similar to Mayerhofer et al. [7] (8 months), and 
may well be influenced by a referral bias to our tertiary center 
[8,13]. We analyzed the factors which can predict the risk of 
metastases using univariate and multivariate analysis. Increas-
ing age was an important risk factor for distant metastases 
with patients ≥50 years having higher risk of metastases. 
Higher FIGO stage and presence of serosal involvement also 
translates into increased risk for metastases. Patients with 
higher FIGO stages, i.e., stage III and stage IV are by definition 
known to have extrauterine disease which usually occurs 
with aggressive histology [22]. We did not find a statistically 
significant correlation between the risk of metastases and his-
topathological parameters like cervical involvement, necrosis, 
and mitotic count. However, studies have shown that cervical 
invasion, in addition to high mitotic count portend poor 
prognosis in ULMS [18,19,23]. The discrepancy with respect to 
cervical involvement in our study can be in part related to the 
low number of patients with cervical involvement. Though 
size is an integral part of FIGO staging and has been shown 
in several studies to influence the patient outcome, it did not 
have significant predictive value for metastases in our study 
[7,22]. Presence of local recurrence increased the risk of distant 
metastases in our study. 
We analyzed the correlation between local recurrence and 
the pattern of distant metastases. Although not statistically 
significant, we found that patients who developed distant 
metastases before local recurrence (21 patients) had a more 
predictable pattern of distant metastases in that lung was 
often (19/21) the first site of metastases in them. In contrast, 
in patients who developed local recurrence before distant 
metastases, the pattern of metastases was unpredictable. It 
can be hypothesized that local recurrence indicates presence 
of viable tumor cells in the surgical bed which makes alternate 
routes of spread including peritoneal spread, possible. This 
is further supported by the statistically significant correlation 
between local recurrence and peritoneal metastases (Fisher 
exact test, p<0.001) in our study. Rose et al. [21] hypothesized 
difference routes of spread in uterine sarcomas to explain the 
different patterns of metastases. While peritoneal disease was 
presumed to be due to direct implantation and nodal disease 
due to lymphatic spread, the lung and other distant sites of 
metastases were thought to result from hematogeneous 
spread. A similar observation was made in our study in that a 
statistically significant correlation was noted between pres-
ence of lung metastases and presence of bone (Fisher exact 
test, p=0.0026), liver (Fisher exact test, p<0.001), and muscle 
(Fisher exact test, p=0.0065), all of which share the common 
hematogeneous route of dissemination.
Giuntoli et al. [3] developed a risk assessment index for 
predicting the outcome in patients with ULMS based on the 
age of the patient, tumor size, FIGO stage, and grade of the 
tumor. In their study of 208 patients with ULMS, stage and 
grade were found to be the most important predictors of 
outcome. Kapp et al. [4] in the their study of 1,396 patients 
with ULMS concluded that African-American race, older age 
at diagnosis, higher stage, and grade at the time of diagnosis 
were associated with poor DSS. The results in our study were 
in agreement with some of these earlier observations. Stage 
specific survival showed that higher stage doubled the risk 
of death for stage IV disease compared to stage I disease. Sree Harsha Tirumani, et al.
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Similarly, presence of local recurrence and advanced age also 
shortened the survival, although the shortening of survival 
with elderly age was minimal. Larger tumor size was associ-
ated with decreased DSS and increased risk of local recurrence 
in the study by Giuntoli et al. [3]. However, in our study tumor 
size neither affected the survival nor the local recurrence-free 
interval.
The limitations of our study were the retrospective study 
design and the selection bias of our cohort treated at our 
tertiary cancer center which may differ from patients in the 
general population. Because of this selection bias, we did not 
calculate the incidence of metastasis in our study which may 
be over-estimated due to the frequent referral of patients with 
advanced disease. We did not assess the impact of certain pa-
rameters like cervical involvement which was not consistently 
evaluated in our study.
In conclusion, we found that ULMS metastasizes most fre-
quently to the lung, peritoneum, bone and liver. Local recur-
rence was often associated with peritoneal spread and lung 
metastases with other sites of hematogeneous metastases in 
our study. The factors which predicted the risk of metastases 
in our study were advanced age and FIGO stage, presence of 
serosal involvement and local recurrence. 
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